GSK Partners Leftover Assets With Academia
Executive Summary
GlaxoSmithKline's Academic Drug Performance Unit isn't focused on what one might expect -trawling academic institutions for promising science and compounds to eventually bring into the fold
You may also be interested in...
Back To School: Big Pharmas Test New Models For Tapping Academia
Pfizer's ambitious tie-ups with multiple research institutions across several cities is but the latest model of academic-industry collaboration, highlighting pharma's ongoing hunger for fresh approaches to drug discovery.
Back To School: Big Pharmas Test New Models For Tapping Academia
Pfizer's ambitious tie-ups with multiple research institutions across several cities is but the latest model of academic-industry collaboration, highlighting pharma's ongoing hunger for fresh approaches to drug discovery.
UK Government Help For Life Sciences Sector Is Welcomed, But Still Not Enough
Therapeutic "clusters" are the next big idea, but unlikely to overshadow industry-academia tie-ups.